Scholar IQ
Help
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Christine E. Horak

ResearcherPublications, citations & collaboration network
184
Works
36,166
Citations
45
h-index
73
i10-index
How has Christine E. Horak's publication output changed over time?
ScholarIQpublication output · 2013–2017

Output grew0% over the shown period — from 1 works in 2013 to 1 in 2017.

1
1
3
1
2013201420152017
What are the most-cited papers on Christine E. Horak?
ScholarIQmost cited works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B.A.G. Haanen, Michele Maio, Iván Márquez‐Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth F. Grossmann, Mario Sznol, Brigitte Dréno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine E. Horak, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20158,191 CitationsOPEN ACCESS
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto
New England Journal of Medicine. 20145,365 CitationsOPEN ACCESS
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, Michael A. Postow, Naiyer A. Rizvi, Alexander M. Lesokhin, Neil H. Segal, Charlotte E. Ariyan, RuthAnn Gordon, Kathleen Reed, Matthew M. Burke, Anne Caldwell, Stephanie Anne Kronenberg, Blessing Agunwamba, Xiaoling Zhang, Israel Lowy, H. David Inzunza, William F. Feely, Christine E. Horak, Quan Hong, Alan J. Korman, Jon M. Wigginton, Ashok Gupta, Mario Sznol
New England Journal of Medicine. 20134,228 CitationsOPEN ACCESS
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi
New England Journal of Medicine. 20152,774 CitationsOPEN ACCESS
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,672 Citations
Related on ScholarIQ
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Paper
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Paper
Nivolumab plus Ipilimumab in Advanced Melanoma
Paper
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Paper
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Paper
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Paper
470M+ articles · free account